Diacerein-loaded dissoluble microneedle as well as preparation method and application thereof
By loading the soluble microneedle with double cerine, polylactic acid-coglycolic acid nanoparticles and hyaluronic acid gel, the problem of low tendon bone healing efficiency is solved, and oxidative stress and inflammation after tendon bone injury is achieved. Reduction promotes tendon bone repair and provides a new way to tendon bone healing.
Patent Information
- Application Number
- CN202411101211.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-08
AI Technical Summary
The healing efficiency after tendon bone injury is low. Existing drugs such as Salserein have short half-life and need to be administered repeatedly, and no problem is found to be effective for tendon bone healing.
Using soluble microneedles loaded with diacerein, polylactic acid-coglycolic acid nanoparticles are used as carriers, combined with hyaluronic acid gel, promotes slow drug release, alleviates oxidative stress and inflammation, restores tendon cell differentiation potential, and promotes Tendon bone healing.
Effectively alleviates oxidative stress after tendon bone injury, reduces inflammation, restores the differentiation potential of tendon cells, promotes tendon bone repair, provides a new way to tendon bone healing, and significantly improves the efficiency of tendon bone repair.
Smart Images

Figure CN118902978A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of nano-drugs, and in particular to a soluble microneedle loaded with diacerein, and a preparation method and application thereof. Background Art
[0002] Tendon-bone tissue is a complex hierarchical tissue that contains key structures at the tendon-bone junction, including tendons, non-calcified fibrocartilage, calcified fibrocartilage, and bone. This structure disperses the stress concentration between tendons and bones. Tendon-bone injuries are common sports system injuries, often occurring in the rotator cuff, Achilles tendon, and patellar tendon. Previous studies have reported that the incidence of rotator cuff injuries alone is as high as 19.0%-32.0%. In the United States, more than 250,000 rotator cuff repair surgeries are performed each year, and the probability of reinjury within 2 years after repair is 11.0%-94.0%. Nearly half of the patients have persistent pain after surgery. Although surgical techniques have developed rapidly in recent years, the repaired tissue rarely returns to a naturally ordered gradient tissue structure, especially in a typical fibrocartilage complex. Therefore, tendon-bone healing remains one of the major challenges facing sports medicine.
[0003] Diacerein is a slow-acting drug for the treatment of osteoarthritis, and its active metabolite is rhein. It is a nonsteroidal anti-inflammatory drug with unique pharmacological properties such as anti-oxidation and anti-apoptosis, and it has also been shown to inhibit interleukin-1 activity. In addition to its therapeutic effects on osteoarthritis, diacerein has also been used in other diseases in recent years. For example, Mansoure et al. reported that diacerein regulated diclofenac-induced acute kidney injury in rats by targeting SIRT1 / HIF-1α / NF-κB and SIRT1 / p53 through its antioxidant, anti-inflammatory, anti-necrosis and anti-apoptotic effects. Refaie reported that diacerein reversed the pathological changes of diabetic cardiomyopathy with its anti-inflammatory, antioxidant and anti-apoptotic properties. Abdel-Aziz et al. found that pretreatment with diacerein had the ability to reverse the harmful effects of pulmonary fibrosis, and diacerein could reduce oxidative stress and inflammatory response in lung tissue by downregulating the TLR4 / NF-κB signaling pathway. However, there are no reports that diacerein has an efficacy in tendon-bone healing. In addition, diacerein has a short half-life. For diseases such as tendon-bone tears that require long-term repair and repeated administration of drugs for in vivo treatment, how to improve the effectiveness of diacerein has also become a difficult problem faced by those skilled in the art. Summary of the invention
[0004] The purpose of the present invention is to provide a soluble microneedle loaded with diacerein and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art. The soluble microneedle loaded with diacerein of the present invention uses polylactic acid-coglycolic acid nanoparticles as carriers, improves the hardness of the microneedle, and can promote the slow release of drugs. The microneedle can reduce oxidative stress after tendon-bone injury, reduce inflammation, restore the tendon-specific differentiation potential of tendon cells under oxidative stress conditions, and promote tendon-bone healing. Provides a new treatment approach for tendon-bone repair.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] The present invention provides an application of a diacerein-loaded soluble microneedle in preparing a medicine or device for promoting tendon-bone healing. The diacerein-loaded soluble microneedle is prepared with polylactic acid-coglycolic acid nanoparticles as a carrier, hyaluronic acid as a gelling agent and diacerein as an active ingredient.
[0007] The present invention also provides a method for preparing a diacerein-loaded soluble microneedle, comprising the following steps:
[0008] (1) preparing polylactic acid-coglycolic acid nanoparticles;
[0009] (2) mixing the polylactic acid-coglycolic acid nanoparticles with diacerein to obtain diacerein nanoparticles;
[0010] (3) mixing the diacerein nanoparticles with hyaluronic acid and shaping them in a microneedle mold to obtain the diacerein-loaded soluble microneedles.
[0011] Preferably, in step (1), the preparation method of the polylactic acid-coglycolic acid nanoparticles is: mixing a dimethyl sulfoxide solution with a polylactic acid-coglycolic acid solution, adding an emulsifier for primary emulsification, then adding an emulsifier again for secondary emulsification, and centrifuging to obtain the polylactic acid-coglycolic acid nanoparticles.
[0012] Preferably, the concentration of the dimethyl sulfoxide solution is 50 μg / μL, and the concentration of the polylactic acid-coglycolic acid solution is 100 mg / mL; the volume ratio of the dimethyl sulfoxide solution to the polylactic acid-coglycolic acid solution is 0.2:1.
[0013] Preferably, the molar ratio of lactic acid to glycolic acid in the polylactic acid-coglycolic acid is 65:35, and the molecular weight of the polylactic acid-coglycolic acid is 40,000-75,000.
[0014] Preferably, the emulsifier is polyvinyl alcohol.
[0015] Preferably, the concentration of polyvinyl alcohol used in the first emulsification is 7%, and the amount used is 3 times the volume of the polylactic acid-coglycolic acid solution; the concentration of polyvinyl alcohol used in the second emulsification is 1%, and the amount used is 50 times the volume of the polylactic acid-coglycolic acid solution.
[0016] Preferably, in step (2), the mass ratio of the polylactic acid-coglycolic acid nanoparticles to the diacerein is 10:(3-5).
[0017] Preferably, in step (3), in step (3), the concentration of the diacerein nanoparticles in the diacerein-loaded soluble microneedles is 1.25-5 mg / ml, and the concentration of the hyaluronic acid in the diacerein-loaded soluble microneedles is 200 mg / ml.
[0018] The present invention also provides a soluble microneedle loaded with diacerein prepared by the preparation method.
[0019] The present invention discloses the following technical effects:
[0020] The invention provides a nanoparticle loaded with diacerein (NPDia), which is mixed with a hydrogel to generate a microneedle, and is named DMN / PLGA@Dia. Figure 1 The preparation process and treatment strategy of DMN / PLGA@Dia. Diacerein can effectively reduce oxidative stress after tendon-bone injury and reduce inflammation. In vitro and in vivo experiments showed that diacerein can restore the tendon-specific differentiation potential of tenocytes under oxidative stress conditions. At the same time, the pathological processes of aging and apoptosis of tenocytes were alleviated. In the immune microenvironment, diacerein weakened inflammatory signals, reduced the levels of proinflammatory cytokines, and increased the levels of anti-inflammatory cytokines. In addition, diacerein can also polarize macrophages to the M2 phenotype, providing a good platform for tissue remodeling. These results show that DMN / PLGA@Dia can promote tendon-bone repair on the basis of alleviating oxidative stress and regulating the immune microenvironment strategy, and can destroy the vicious cycle between ROS accumulation and M1 polarization after macrophage injury, and promote tendon-bone healing. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0022] Figure 1 The preparation flow chart and treatment strategy diagram of DMN / PLGA@Dia;
[0023] Figure 2 The biomechanical test results of the Achilles tendon-bone tissue after repair; (A): Instron testing machine; (B): The placement state of the Achilles tendon; (C): Load-displacement curve;
[0024] Figure 3 Results of gene expression analysis related to tendon-bone injury and evaluation of oxidative stress response after tendon-bone injury; (A): Volcano plot; (B): Heat map of differentially expressed genes; (C): GO functional enrichment analysis of differentially expressed genes; (D) PPI protein network analysis of differentially expressed genes; (E): KEGG analysis of genes; (F): Expression level of IL-1β mRNA in the expression matrix; (G): ELISA results of ROS / RNS, MDA, IL-1β, and SOD levels in normal rats and at different time points after tendon-bone injury; **P<0.01;
[0025] Figure 4 Figure 3 shows the protective effect of NPDia on tenocytes induced by H2O2-induced oxidative stress; (A): Tenocyte viability after treatment with different concentrations of NPDia for different time periods (n=3); (B): Cell viability of tenocytes exposed to H2O2 and / or H2O2 (n=3); (C): Representative images of ROS in tenocytes of different treatment groups, scale bar=100μm; (D): SAβ-gal staining results of tenocytes of different treatment groups, scale bar=100μm; (E): Expression of SCX, Col-I and Bax in tenocytes of different treatment groups; (F): Quantitative analysis of the number of ROS-positive cells in C (n=5); (G): Semiquantitative analysis of the percentage of positive cells in D (HJ): Representative Western blot results of SCX, Col-I and Bax in E (n=3); (K): Flow cytometry analysis results of apoptotic tenocytes in different treatment groups; (L): The proportion of late apoptotic positive tenocytes in K (n=3); (M): TUNEL immunofluorescence staining results of apoptotic tenocytes in different treatment groups, scale bar = 100 μm; (N): Semi-quantitative analysis results of the percentage of positive cells in M (n=3); (OQ): ELISA was used to determine the ROS / RNS, MDA and SOD contents of tenocytes in different treatment groups (n=3); *P<0.05**P<0.01; ***P<0.001;
[0026] Figure 5The regulatory effect of NPDia on LPS-induced oxidative stress macrophage polarization; (A): Representative images of ROS in macrophages of different treatment groups, scale bar = 50 μm; (B): Quantitative analysis results of ROS-positive cell counts in A (n = 3); (C): Immunofluorescence staining of MI macrophages and total macrophages in different treatment groups, scale bar = 50 μm; (D): Immunofluorescence staining of M2 macrophages and total macrophages in different treatment groups, scale bar = 50 μm; (E): Semi-quantitative analysis results of M1 macrophage percentage in C (n = 3); (F): Semi-quantitative analysis results of M2 macrophage percentage in D; (GI) Contents of TNF-α, IL-1β and IL-6 in macrophages of different treatment groups (n = 3); *P < 0.05; **P < 0.01; ***P < 0.001;
[0027] Figure 6 Characteristic analysis results of DMN / PLGA@Dia; (A): SEM (left) and TEM (right) images of NPDia; (B): Particle size analysis results of NPDia; (C): Fluidity observation results of the mixture of NPDia and hyaluronic acid; (D): Schematic diagram of the preparation process of DMN / PLGA@Dia; (E): Appearance of DMN / PLGA@Dia; (F): SEM image of DMN / PLGA@Dia; (G): Typical fluorescence image of DMN / PLGARDB in cross section and longitudinal sections; (H): Typical ultra-depth microscopy images of DMN / PLGA@Dia; (I): H&E staining images after microneedles were inserted into the skin; (JN): Hardness (J), adhesion (K), elasticity (L), cohesion (M) and elasticity (N) of DMN / PLGA@Dia at different concentrations; *P<0.05; **P<0.01; ***P<0.001; The horizontal axes of (J)-(N) are MN, Low-dose, Middle-dose, High-dose from left to right;
[0028] Figure 7 DMN@PLGA Dir Nanoparticle release from microneedles; (A): DMN@PLGA DirTypical fluorescence images of rats; (B): In vivo images of rats after 1 day of microneedle insertion; (C): In vivo images of rats after 2 days, 3 days, 4 days, 5 days, 6 days and 7 days of microneedle insertion; (D): Data analysis results of fluorescence intensity in C; (E): In vitro images of skinless ankle joints on days 3 and 7; (F): In vitro images of heart, liver, spleen, lung and kidney on days 3 and 7; (G): Data analysis of fluorescence intensity in ankle joints (n=3); (H): Data analysis of fluorescence intensity in kidneys (n=3); (I): Data analysis of fluorescence intensity in spleen (n=3); (J): Data analysis of fluorescence intensity in liver (n=3); (K): Data analysis of fluorescence intensity in heart (n=3); (L): Data analysis of fluorescence intensity in lungs (n=3); *P<0.05; **P<0.01; ***P<0.001;
[0029] Figure 8 The protective effect of DMN / PLGA@Dia on damaged tendon-bone tissue; (AC): Relative levels of ROS / RNS, MDA and SOD in tendon-bone insertion tissue at 4 weeks (n=3); (DF): Relative levels of ROS / RNS, MDA and SOD in tendon-bone insertion tissue at 8 weeks (n=3); (G): Typical images of repaired Achilles tendon-bone tissue in different treatment groups at 4 and 8 weeks; (H): Maximum load of Achilles tendon-bone tissue in different groups at 4 weeks (n=6); (I): Maximum load of Achilles tendon-bone tissue in different groups (n=6); (J): Expression levels of SCX, Col I and Col III in Achilles tendon-bone tissue in different groups; (K): Expression levels of Col I, ColIII and SCX in Achilles tendon-bone tissue in different treatment groups at 8 weeks; (LN): Expression levels of SCX, Col I and Col III in Achilles tendon-bone tissue in different treatment groups at 4 weeks. Representative immunoblot detection of SCX, Col I and Col III in Achilles tendon-bone tissues of different treatment groups at 8 weeks (n=3); (OQ): Representative immunoblot detection of SCX, Col I and Col III in Achilles tendon-bone tissues of different treatment groups at 8 weeks (n=3); *P<0.05; **P<0.01; ***P<0.001; The horizontal axes of (A)-(F), (H)-(I), (L)-(Q) are Control, NC, Low-dose, Middle-dose, High-dose from left to right;
[0030] Fig. 9Figure 4 shows the promoting effect of DMN / PLGA@Dia on tendon-bone healing; (A): Typical H&E staining, Masson staining, Safranin O staining and Sirius red staining images of different groups at 4 and 8 weeks, scale bar = 100 μm; (B): Histological evaluation of Achilles tendon-bone tissues in different groups at 4 weeks by TMSS method (n = 3); (C): Modified Bonar score for histological evaluation of Achilles tendon-bone tissues in different groups at 4 weeks (n = 3); (D): Semi-quantitative analysis of Col I content in Achilles tendon-bone tissues at 4 weeks (n = 3); (E): Histological evaluation of Achilles tendon-bone tissues in different groups at 8 weeks by TMSS method (n = 3); (F): Modified bonar score for histological evaluation of Achilles tendon-bone tissues in different groups at 8 weeks (n = 3); (G): Col I content in Achilles tendon-bone tissues at 8 weeks (H): Typical immunohistochemical staining images of Col I and Col III in Achilles tendon-bone tissue at 4 weeks, scale bar = 100 μm; (I) Semi-quantitative analysis of Col I content in Achilles tendon-bone tissue at 4 weeks (n = 3), scale bar = 100 μm; (J): Semi-quantitative analysis of Col III content in Achilles tendon-bone tissue at 4 weeks (n = 3); (K): Typical immunohistochemical staining images of Col I and Col III in Achilles tendon-bone tissue at 8 weeks; (L): Semi-quantitative analysis of Col I content in Achilles tendon-bone tissue at 8 weeks (n = 3); (M): Semi-quantitative analysis of Col I content in Achilles tendon-bone tissue at 8 weeks Semi-quantitative analysis of III content (n=3); *P<0.05; **P<0.01; ***P<0.001; The horizontal coordinates of (B)-(G), (I)-(J), and (L)-(M) from left to right are Control, NC, Low-dose, Middle-dose, and High-dose;
[0031] Fig.10The therapeutic effect of DMN / PLGA@Dia on the rat model of Achilles tendon-bone insertion injury; (A): Representative CatWalk footprint images and gait accuracy analysis of different groups at 4 weeks; (B): Representative CatWalk footprint images and gait accuracy analysis of different groups at 8 weeks; (CH): The three parameters of footprint analysis of different groups at 4 weeks were used to quantify hindlimb function, including (CD) stance time, (EF) speed, and (GH) step length (n=4); (IN): The three parameters of footprint analysis of different groups at 8 weeks were used to quantify hindlimb function, including (IJ) stance time, (KL) speed, and (MN) step length (n=4); *P<0.05; **P<0.01; ***P<0.001; The horizontal axes of (C)-(N) are Control, NC, Low-dose, Middle-dose, and High-dose from left to right;
[0032] Fig.11 The therapeutic effect of DMN / PLGA@Dia on paw stress in the rat model of Achilles tendon-bone insertion injury; (A): Representative CatWalk hind paw footprint images of different groups and stress maps at 4 weeks; (B): Representative CatWalk hind paw footprint images of different groups and stress maps at 8 weeks;
[0033] Fig.12Figure 2 shows the regulatory effect of DMN / PLGA@Dia on polarization of oxidative stress macrophages; (A): Typical fluorescence images of cell nuclei (DAPI; blue) and CD86 (red) in Achilles tendon-bone tissue at 4 weeks, scale bar = 100 μm; (B): Typical fluorescence images of cell nuclei (DAPI; blue) and CD206 (red) in Achilles tendon-bone tissue at 4 weeks, scale bar = 100 μm; (C): CD86 content in Achilles tendon-bone tissue at 4 weeks Semi-quantitative analysis of CD206 content in Achilles tendon-bone tissue at 4 weeks (n=3); (E): Typical fluorescence images of cell nuclei (DAPI; blue) and CD86 (red) in Achilles tendon-bone tissue at 8 weeks, scale bar = 100 μm; (F): Typical fluorescence images of cell nuclei (DAPI; blue) and CD206 (red) in Achilles tendon-bone tissue at 8 weeks, scale bar = 100 μm; (G): Semi-quantitative analysis of CD86 content in Achilles tendon-bone tissue at 8 weeks (n=3); (H): Semi-quantitative analysis of CD206 content in Achilles tendon-bone tissue at 8 weeks (n=3); (IL): Expression of cytokines associated with M1 macrophage phenotype detected by ELISA; including IL-1β (I; K) and TNF-α (J; L) at 4 and 8 weeks (n=3); (MR): Expression of cytokines associated with M2 macrophage phenotype detected by ELISA; including IL-6 (M, P), IL-4 (N, Q) and IL-10 (O, R) at 4 and 8 weeks (n=3); *P<0.05; **P<0.01; ***P<0.001; The horizontal axes of (C)-(D), (G)-(H), (I)-(R) are Control, NC, Low-dose, Middle-dose, High-dose from left to right;
[0034] Fig.13 The results of biosafety verification of DMN / PLGA@Dia in vivo; (AB): Typical H&E staining images of heart, liver, spleen, lung and kidney in different groups at 4 and 8 weeks, scale bar = 100 μm; (CK): Blood biochemical test 4 weeks after surgery, including blood routine (CE), renal function (FG) and liver function (HK) (n = 3); (LT): Blood biochemical test 8 weeks after surgery, including blood test (LN), renal function test (OP) and liver function test (QT) (n = 3); The horizontal axes of (C)-(T) are Control, NC, Low-dose, Middle-dose and High-dose from left to right;
[0035] Fig.14The results of hemolysis analysis of NPDia; (A): Typical image of hemolysis analysis; (B): Quantitative analysis of nanoparticle-induced hemolysis rate (n=3); ***P<0.001. DETAILED DESCRIPTION
[0036] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0037] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0038] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0039] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0040] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0041] Example 1
[0042] 1. Materials and Methods
[0043] 1. Materials
[0044] Diacerein (Dia), 30% H2O2 solution and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, USA). Polylactic-co-glycolic acid (PLGA) was purchased from Sigma (Cat. No. P2066). Low molecular weight hyaluronic acid (20 kDa) was purchased from Bloomage Biotech Co., Ltd. (Jinan, China). Reactive oxygen species detection kit, lipid peroxidation MDA detection kit, WST-8 total superoxide dismutase detection kit, one-step TUNEL apoptosis detection kit, CKK-8 and DAPI staining solution were purchased from Beyotime Biotech (Shanghai, China). Annexin V-FITC / PI apoptosis kit was purchased from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China). Antibodies to type I collagen, type III collagen, SCX, CD68, CD206 and CD86 were purchased from Wuhan Tri-Eagle Technology Co., Ltd. (Wuhan, China). Western blot secondary antibodies, anti-rabbit / mouse IgG-conjugated IRDye600 and IRDye800 were purchased from Rockland Gilbertsville, CA, USA. Immunohistochemistry detection kit (anti-rabbit secondary antibody), DAB kit, hematoxylin and eosin (H&E) high-definition constant staining kit, and Masson's trichrome staining solution were purchased from Wuhan Solebao Biotechnology Co., Ltd. (Wuhan, China). Sirius red staining solution was purchased from Feijing Biotechnology Co., Ltd. (Fuzhou, China). Cell senescence detection kit (β-galactosidase method) was purchased from Aibixin Technology Co., Ltd. (Wuhan, China). 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyaine iodide (DiR) and goat anti-rabbit IgG Fc, cross-adsorbed secondary antibodies, AlexaFluor TM 594 was purchased from Invitrogen (Carlsbad, CA, USA). OxiSelect ROS / RNS detection kit was purchased from Cell Biolabs (CA, USA). Other ELISA kits were purchased from Jiangsu Jingmei Biotechnology Co., Ltd. (Yancheng, China). RPMI 1640 medium, trypsin-EDTA, fetal bovine serum (FBS), and PBS were purchased from Gibco (Grand Island, NY, USA).
[0045] 2. Data processing and function annotation
[0046] The gene expression profiles related to tendon-bone injury were retrieved and downloaded from the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). The gene expression profile of GSE103266 was downloaded and background correction, normalization, and logarithmic transformation were performed using the Limma software package. P < 0.05 and logFC ≥ 1 were used as the screening criteria for differentially expressed genes (genes). Then, enrichment analysis was performed using a cluster analyzer, including GO and KEGG analysis.
[0047] 3. Construction of PPI network
[0048] The STRING database is an online search tool for analyzing known proteins and predicting PPI networks, including direct and indirect interactions between proteins and their functional relevance (https: / / string-db.org / ). Genes with a comprehensive score > 0.4 were imported into the STRING platform, and the PPI network was constructed using Cytoscape.
[0049] 4. Preparation and characterization of drug encapsulated nanoparticles
[0050] The double emulsion solvent evaporation technique was used to prepare diacerein-loaded nanoparticles. The specific process is as follows:
[0051] 200 μL DMSO solution (50 μg / μL) was mixed with 1 mL PLGA (100 mg / mL, lactic acid to glycolic acid ratio of 65:35, molecular weight = 40000-75000, dissolved in dichloromethane) solution, and then the above mixture was mixed with 3 mL 7% PVA (molecular weight = 14160) solution using an ultrasonic homogenizer (ultrasound HD 2070, with electronics, Berlin, Germany) and then ice-bathed for 0.5 min. Then, the resulting emulsion was added to 50 mL of 1% PVA solution, further emulsified by ultrasonic treatment for 1 min, and then stirred for 24 h to completely evaporate the dichloromethane at room temperature. The nanoparticles were collected, washed 3 times with distilled water, and centrifuged at 15000 rpm for 5 min. Finally, the nanoparticles were collected and resuspended in deionized water for subsequent studies.
[0052] A solution containing 50 mg of Dia was mixed with a solution containing 100 mg of PLGA nanoparticles to form nanoparticles loaded with Dia (NPDia). A rhodamine (RDB) solution was added to the PLGA nanoparticle solution to form nanoparticles loaded with RDB (NPRDB). The morphology of the two-medium coated nanoparticles was characterized using scanning electron microscopy (SEM) and transmission electron microscopy (TEM). The size of the drug-encapsulated nanoparticles was measured by dynamic light scattering (DLS) using a dynamic light scattering instrument 3000 laser particle size analyzer (Malvern Instruments Ltd., Malvern, UK). The encapsulation rate of the nanoparticle-loaded diacerein was 74%.
[0053] 5. Cultivation of Tenocytes and Macrophages
[0054] 4-week-old SD rats were euthanized under anesthesia. After cleaning and disinfection, the ankle joint was cut open and the Achilles tendon tissue was taken. After washing with sterile PBS for more than 6 times, the Achilles tendon tissue was cut into small pieces with sterile scissors, and the fragmented tissue was placed in a 5mg / mL type I collagenase solution. After 2h, the tissue was digested into flocculent substances. Then, it was filtered into a 50mL centrifuge tube with a 70μm cell sieve, and the resulting digestion solution was centrifuged at 1000g for 5 minutes, and the supernatant was discarded. Finally, the cell suspension was cultured in complete culture medium (90% DMEM, 10% fetal bovine serum, 100mg / mL streptomycin, 100U / mL penicillin). The culture dish was cultured at 37°C and 5% CO2.
[0055] 8-week-old SD rats were fasted one day before anesthesia and euthanized under anesthesia. After cleaning and disinfection, the mice were transferred to a clean workbench. The fur layer was opened with sterile scissors and forceps to expose the abdominal muscles. After disinfection with medical cotton balls, about 15mL of 1640 culture medium containing 10% fetal bovine serum, 100mg / mL streptomycin and 100U / mL penicillin was injected into the abdominal cavity with a syringe. Then massage the abdomen with medical cotton balls for 3 minutes and wait for 5 minutes. Then cut a small hole in the abdominal muscle with new scissors. The peritoneal fluid and culture medium were extracted with a sterile pipette. After centrifugation at 1000rpm for 5 minutes, the cells were resuspended and cultured in a culture dish. After 4h, the old culture medium was replaced with fresh 1640 culture medium.
[0056] 6. Cell Viability
[0057] Cell counting kit-8 (CCK-8) was used to detect cell viability after treatment with NPDia at different concentrations (0, 10, 20, 30, 40, 50, 100, 200, 500 μM, obtained by dilution of NPDia in "4. Preparation and characterization of drug-encapsulated nanoparticles"). First, rat tenocytes were evenly seeded in a 96-well plate. When the cell confluence reached about 80%, different concentrations of NPDia were added, and the supernatant was taken at 12h, 24h and 48h. Then, 100 μL of fresh culture medium and 10 μL of CCK-8 solution were added to each well, and the cells were cultured continuously in a cell culture incubator for 2h. Finally, the absorbance of each well was measured at a wavelength of 450nm using a molecular device (SpectraMax M5, MDC, Sunnyvale, CA, USA). At the same time, the optimal concentration of NPDia was determined, and subsequent experiments were carried out at this concentration.
[0058] 7. TUNEL staining
[0059] TUNEL staining kit was used to detect cell apoptosis. The specific process was as follows: the cells were divided into 4 groups: H2O2+Dia group: rat tendon cells were treated with 3×10 3 The cells were seeded at a density of 1×10 cells / well in a 96-well plate and stimulated with NPDia for 24 h. -4 MH2O2 stimulation for 4 h. Dia group: cells were first stimulated with NPDia for 24 h, and then treated with saline equal to H2O2 for 4 h. H2O2 group: cells were first treated with saline equal to NPDia for 24 h, and then treated with 1×10 -4 M H2O2 was stimulated for 4 h. Control group: NPDia and H2O2 were replaced with an equal amount of normal saline. The cells were then permeabilized with proteinase K, and TUNEL reaction buffer was added for 60 min. Subsequently, the slices were observed and recorded using a fluorescence microscope (Leica DMR 3000; Leica, Germany).
[0060] 8. β-Galactosidase staining
[0061] β-galactosidase staining was performed according to standard procedures. Cell grouping and processing methods were the same as "7. TUNEL staining". Rat tenocytes were then washed once with PBS and fixed with β-galactosidase staining solution for 15 minutes. After removing the fixative, the cells were washed three times with PBS, and then the staining working solution was added and incubated at 37°C overnight. The number of β-gal-positive cells was calculated by counting 150-200 cells in 6 random microscopic fields.
[0062] 9. ROS level determination
[0063] ROS detection kit was used to detect ROS levels in rat tenocytes. Cell grouping and treatment methods were the same as "7. TUNEL staining". DCFH-DA probe was mixed with the cell culture medium of each treatment group and diluted to the working concentration. After incubation for 20 min, the cell plate was observed and images were taken using a fluorescence microscope (Leica DMR 3000; Leica, Germany).
[0064] 10. Immunoblotting analysis of cellular proteins
[0065] Different groups of rat tenocytes were treated with RIPA lysis buffer containing protease inhibitors, and the cell grouping and treatment methods were the same as "7. TUNEL staining". The lysate was collected and denatured by boiling. The protein samples were separated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylidene fluoride (PVDF) membranes to block (5% skim milk) for 1.5 h. Then, the cell membranes were incubated with antibodies (Col I, 1:1000; Bax, 1:1000; SCX, 1:1000) at 4°C overnight. The next day, the membranes were washed and further incubated with secondary antibodies, anti-rabbit / mouse IgG-conjugated IRDye600 or IRDye800 (1:10000) at 4°C overnight. Finally, the membranes were visualized using the Odyssey infrared imaging system (LI-COR, Linkon, NE, USA). The optical density of each band on the membrane was quantified using Image J software. β-actin was used as a reference.
[0066] 11. Enzyme-linked immunosorbent assay (ELISA)
[0067] ELISA was used to measure the oxidative stress level, antioxidant capacity, and inflammation-related cytokines. After obtaining the cell supernatant or tissue lysate, the ROS / RNS level was measured using the OxiSelect ROS / RNS detection kit according to the manufacturer's instructions. The ELISA kit also measured the concentration of MDA and SOD according to the standard instructions. The cytokines related to inflammation were quantified using the ELISA kit according to the manufacturer's instructions.
[0068] 12. Immunofluorescence detection of macrophages
[0069] Macrophages were divided into three groups: LPS+Dia group: macrophages + 100 ng / mL LPS + NPDia; LPS group: macrophages + 100 ng / mL LPS + equal amount of saline; Control group: macrophages + equal amount of saline + equal amount of saline. Macrophages in different groups were washed twice with PBS and fixed with 4% PFA. After blocking with 1% BSA, the samples were placed in primary antibodies of anti-cd206 (1:200), anti-cd86 (1:200), and anti-cd68 (1:200) and incubated overnight at 4°C. The samples were then washed with PBS, and secondary antibodies (1:200) were added and reacted at room temperature for about 1 h. Finally, the nuclei were stained with DAPI for 5 min. Each slide was photographed with a fluorescence microscope (Leica DMR 3000; Leica, Germany).
[0070] 13. Production process and characteristics analysis of soluble microneedles
[0071] Low molecular weight hyaluronic acid was dissolved in NPDia solutions of different concentrations (0, 1.25 mg / ml, 2.5 mg / ml, and 5 mg / ml, respectively) to make a final concentration of hyaluronic acid of 200 mg / ml. Centrifuge at 4000g for 20 minutes and mix thoroughly to obtain a mixture HA@PLGA / Dia, and observe the appearance of the mixture. The mixture was then placed in a polydimethylsiloxane (PMDS) mold and covered with a lid. Centrifuge again at 4000g for 20 minutes, and then remove the lid. After thorough drying, soluble microneedles (DMN / PLGA@Dia) were obtained. The same method was used to prepare soluble microneedles loaded with NPRDB (DMN / PLGA RDB ).
[0072] The morphology of DMN / PLGA@Dia was characterized using a mobile phone camera, scanning electron microscope (SEM), and ultra-deep 3D microscope (Leica, Germany). RDB The MNs were analyzed using a fluorescence microscope (Leica DMR 3000; Leica, Germany). The hardness, adhesion, elasticity, adhesion, and elasticity of the MNs were measured using a texture analyzer (FTC TMS-PRO, USA).
[0073] 14. Establishment of animal model
[0074] All animal experimental designs and procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Nantong University School of Medicine. A total of 60 8-week-old SD rats were used to establish the Achilles tendon-bone insertion injury rat model and were equally divided into 5 groups: control group; NC group: surgical repair, DMN / PLGA@Dia treatment without NPDia once a week; low-dose group: DMN / PLGA@Dia treatment with 1.25 mg / ml NPDia once a week; medium-dose group: DMN / PLGA@Dia treatment with 2.5 mg / ml NPDia once a week; high-dose group: DMN / PLGA@Dia treatment with 5 mg / ml NPDia once a week. There were 12 rats in each group. Six rats in each group were euthanized at week 4, and the remaining rats were euthanized at week 8.
[0075] Establishment of Achilles tendon-bone insertion injury model: Both ankles of each rat were included in the experiment. An L-shaped incision was made on the lateral side of the ankle joint, and the skin was cut. The soft tissue was covered with a hook, and the calcaneus and Achilles tendon were exposed layer by layer. The Achilles tendon was about 4 mm from the insertion point to the tendon junction. Two intramedullary tunnels (0.5 mm in diameter) were created on the calcaneus using a small electric drill, and the Achilles tendon was reattached to the footprint using 5-0 polypropylene sutures (Ethicon, Somerville, USA). The muscle incision was closed using 5-0 polypropylene sutures. The incision was sutured with 4-0 black silk sutures. 80,000 U of penicillin was injected for 3 consecutive days after surgery. After 1 week, after the swelling of the rat ankle subsided, DMN / PLGA@Dia was applied to the wound for treatment. The modified histomorphometric scoring system and modified Bonar score were used to evaluate the histological changes around the repaired insertion (Tables 1 and 2).
[0076] Table 1
[0077]
[0078]
[0079] Note: +, positive; C, continuity; F, fibrocartilage; R, regularity; T, tide mark
[0080] Table 2
[0081]
[0082] 15. Gait analysis
[0083] To examine the functional recovery of the rats, gait analysis tests were performed on the rats at 4 and 8 weeks. The gait analysis system consists of a glass track containing light from a white fluorescent light source. The light from this light source is completely reflected internally. When an object comes into contact with the glass track, the light is reflected downward and detected by a camera. The signal is then digitized and analyzed by the gait analysis program software. Gait analysis can be used to measure a variety of static and dynamic gait parameters. Some of these parameters, including the average strength of paw placement, stance time, and swing time, are associated with mechanical hyperalgesia and neuropathic pain. The following hindpaw parameters were used: right and left hindpaw stance, right and left hindpaw swing speed, right and left hindpaw stride length. Video analysis of the rats from each experimental group was performed using the gait analysis software (Noldus, Wageningen, The Netherlands) version 9.0 for Windows.
[0084] 16. Immunoblotting of tissue proteins
[0085] The Achilles tendon part near the calcaneus was treated with RIPA lysis buffer containing protease inhibitors. The lysate was collected and denatured by boiling. The protein samples were separated by electrophoresis on 6-12% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene fluoride (PVDF) membranes for blocking (5% skim milk) for 1.5 h. Then, the membranes were incubated with antibodies (ColI, 1:1000; Col III, 1:1000; SCX, 1:1000) at 4°C overnight. The next day, the membranes were washed and incubated with secondary antibodies anti-rabbit / mouse IgG conjugated to IRDye600 or IRDye800 (1:10000) at 4°C overnight. Finally, the membranes were visualized using the Odyssey infrared imaging system (LI-COR, Linkon, NE, USA). The optical density of each band on the membrane was quantified using Image J software. β-actin was used as a reference.
[0086] 17. Masson staining, safranin O staining and HE staining
[0087] Ankle joint tissues from rats in different groups were taken and fixed with 4% paraformaldehyde at room temperature for 24 h. These tissues were decalcified for four weeks. Then, 5 μm sections were cut on a paraffin microtome and rehydrated. Masson staining, Safranin O staining, and H&E staining were performed according to standard procedures. After imaging the stained specimens, inflammation and collagen fibers, including their organization and deposition, were analyzed. Paraffin sections were performed on the heart, liver, spleen, lung, and kidney of different groups. H&E staining was used to evaluate the biocompatibility of DMN / PLGA@Dia.
[0088] 18. Sirius red staining
[0089] 5-μm-thick sections were cut on a paraffin microtome and rehydrated. After rehydration, Sirius red staining was performed according to standard procedures. Collagen birefringence and chondrogenesis were evaluated under polarized light microscopy to detect differences in collagen and cartilage deposition (Leica DMR3000; Leica, Germany). The rotation of the polarization angle of the microscope was set at the same angle to obtain all images, because the rotation of the polarization angle can change the color of collagen fibers. Relatively thin and disordered fibers are stained green, representing type III collagen or fibrochondrocytes, while thicker fibers are stained orange-yellow, representing type I collagen.
[0090] 19. Immunohistochemical staining
[0091] 5 μm thick sections were cut on a paraffin microtome and rehydrated for immunohistochemical analysis. After blocking, the slides were incubated with antibodies (ColI, 1:200; Col III, 1:200) at 4 °C overnight. Then they were incubated with secondary antibodies at 37 °C for 2 h. Finally, 3,3-diaminobenzidine (DAB) and hematoxylin were stained, and the slides were sealed and observed under a microscope (Leica DMR 3000; Leica, Germany).
[0092] 20. Immunofluorescence detection of tissue sections
[0093] Tissue sections were blocked with blocking reagent containing 0.3% Triton X-100 for 1.5 h. They were then stained with antibodies (CD68, 1:200; CD206, 1:200) at 4 °C overnight. Then, they were incubated with secondary antibodies at 37 °C for 2 h. After washing, the slides were stained with DAPI and observed under a microscope (Leica DMR 3000; Leica, Germany).
[0094] 21. In vivo evaluation of nanoparticle release after microneedle insertion
[0095] In order to evaluate the release of nanoparticles after microneedle insertion, DMN@PLGA was prepared according to the methods described in “4. Preparation and characterization of drug-encapsulated nanoparticles” and “13. Fabrication process and characterization of soluble microneedles”. Dir (Use Dir instead of Dia) microneedle. Using the Achilles tendon-bone insertion injury rat model, DMN@PLGA was used to reduce ankle swelling. Dir Placed on the surface of the rat ankle skin. In vivo imaging was performed using TanonABLX6 (Tanon Technology Co., Ltd., Shanghai, China) on 1d, 2d, 3d, 4d, 5d, 6d, and 7d. On the 3d and 7d, the rat ankle was removed and the surface skin was removed. In vitro imaging was performed on the rat heart, liver, spleen, lung, and kidney.
[0096] 22. Biomechanical testing
[0097] The specimens were slightly separated from the surrounding tissue and completely removed along the entire length to test the healing strength using an Instron testing machine (Model 3365; Intstlcon). The two ends of the Achilles tendon were clamped in the upper and lower clamps, and the repair site was fixed in the middle of the two clamps. The upper clamp holding one end was pulled out at a constant speed of 25 mm / min until the Achilles tendon-bone connection was ruptured. The load-displacement curve recorded by the testing software program showed a sharp drop, representing the rupture of the repair ( Figure 2 ).
[0098] 23. Statistical analysis
[0099] Data are presented as mean ± standard deviation. For data from three or more groups, if the variance was not uniform, nonparametric tests were performed. If the variance met homogeneity, one-way analysis of variance was performed. Once the test was statistically significant, any two groups were compared using Fisher's least significant difference test. P < 0.05 was set as statistically significant.
[0100] 2. Results and Discussion
[0101] 1. Evaluation of oxidative stress after tendon-bone injury
[0102] In this example, the GSE103266 dataset was selected, which includes 4 human control samples and 12 rotator cuff injury samples. Using the Limma software package, a total of 233 down-regulated genes and 536 up-regulated genes were found ( Figure 3 A and B). GO functional enrichment analysis showed that these differentially expressed genes were significantly associated with immune activation and oxidative stress signaling pathways ( Figure 3 C). PPI protein network analysis showed that these genes have crosstalk at the protein level ( Figure 3 D). The functions of these genes were further elucidated using KEGG analysis. KEGG enrichment analysis showed that the oxidative stress pathway was highly enriched in the rotator cuff injury group, indicating that cellular oxidative stress may be involved in the repair process of acute rotator cuff injury ( Figure 3 E). In the expression matrix, the mRNA expression levels of IL-1β were analyzed separately. The results showed that the mRNA expression level of IL-1β was significantly increased after rotator cuff injury ( Figure 3 F).
[0103] To verify that Achilles tendon-bone insertion is similar to rotator cuff injury, and that there is also persistent oxidative stress after injury, normal tissues of normal rats and tissues of rats with Achilles tendon-bone insertion injury were extracted 2 weeks, 4 weeks, and 8 weeks after injury to detect ROS / RNS, MDA, IL-1β, and SOD levels. The results showed that after Achilles tendon-bone insertion injury, ROS / RNS, MDA, and IL-1β levels continued to increase, and the content of the antioxidant stress kinase SOD decreased ( Figure 3 G, ROS / RNS, MDA, and IL-1β were taken as the normal group as the reference, and SOD was taken as the 2-week group as the reference).
[0104] 2. Diacerein reduces oxidative stress and restores the specific differentiation potential of tenocytes in vitro
[0105] First, the cell viability of different concentrations of diacerein was tested at 12, 24, and 48 hours. The results showed that at a concentration of 30 μM NPDia, the cell viability of tenocytes was the best after 24 hours of culture ( Figure 4A). Therefore, in the following experiments, tenocytes from all diacerein-treated groups were pre-stimulated with 30 μM NPDia for 24 h. -4 M H2O2 was used to stimulate tendon cells to simulate the state of oxidative stress in normal tendon cells. The results showed that after H2O2 stimulation of tendon cells, the activity of tendon cells decreased significantly, while pre-stimulation with diacerein could improve this effect ( Figure 4 B). Then, the DCFH-DA probe was used to detect the total ROS level. The results showed that the relative number of DCFH-DA fluorescence positive cells in the H2O2 group was significantly higher than that in the control group, and the relative number of DCFH-DA fluorescence positive cells in the H2O2+Dia group was significantly lower than that in the H2O2 group ( Figure 4 In addition, the contents of ROS / RNS, MDA and SOD in tenocytes treated with diacerein and then exposed to H2O2 were detected by ELISA ( Figure 4 The results showed that the levels of ROS / RNS and MDA in the H2O2 group were significantly increased, and the level of SOD was significantly decreased compared with the control group and H2O2+Dia group.
[0106] H2O2 can simulate an oxidative stress environment and inhibit the proliferation and differentiation of tendon cells. Therefore, diacerein, which has the ability to scavenge ROS, was used to study whether they could reduce the inhibitory effect of H2O2 on the tendinous differentiation potential of tendon cells. Type I collagen is the main component of the extracellular matrix synthesized by tendon cells in normal tendons. In addition, SCX is one of the key transcription factors in tendon formation and is essential for tendon lineage differentiation. The expression levels of Col-I and SCX in tenocytes of different groups were detected by Western blot ( Figure 4 The results showed that the expression of Col-I and SCX in the H2O2 group was significantly decreased compared with the control group and the H2O2+Dia group. Diacerein pretreated tenocytes can still retain some tendon differentiation potential after exposure to oxidative stress microenvironment ( Figure 4 I and J).
[0107] Severe oxidative stress can lead to apoptosis of tenocytes. Western blotting, TUNEL staining, and Annexin V-FITC / PI-labeled flow cytometry were used to analyze apoptotic tenocytes. Western blotting results showed that the expression of Bax in the H2O2 group was significantly increased compared with the control group and the Dia group, while the expression of Bax in the H2O2 group was significantly increased compared with the H2O2 group ( Figure 4 The expression of Bax in the H2O2+Dia group was significantly decreased. The percentage of late apoptosis-positive tenocytes decreased from 37.4±5.22% in the H2O2 group ( Figure 4The K and L of the H2O2+Dia group were reduced to 21±2.93%. The ratio of TUNEL-positive cells was also significantly reduced ( Figure 4 In addition, senescence-related β-galactosidase staining showed that diacerein inhibited the senescence of tendon cells under oxidative stress ( Figure 4 D and G).
[0108] 3. Diacerein regulates macrophage M1 / M2 polarization
[0109] Lipopolysaccharide (LPS) can stimulate M1 macrophage polarization in a ROS-dependent manner and is a widely accepted in vitro proinflammatory model. Therefore, the LPS-induced model was used to evaluate the ROS clearance and macrophage polarization regulation of diacerein in primary macrophages. The total ROS level was detected by DCFH-DA, and LPS induction significantly triggered the accumulation of ROS in macrophages. The results showed that NPDia could effectively inhibit LPS-induced ROS production and accelerate ROS clearance ( Figure 5 A and B). Subsequently, immunofluorescence staining of CD86 (a specific marker for M1 macrophages) and CD206 (a specific marker for M2 macrophages) was used to explore the polarization of macrophages. After LPS stimulation, the CD86 fluorescence signal increased significantly, while the CD206 fluorescence signal decreased significantly. However, the use of NPDia significantly increased the expression of CD206 ( Figure 5 In addition, ELISA results also showed that NPDia significantly reduced the levels of inflammatory factors TNF-α and IL-1β compared with the LPS group ( Figure 5 These data support the view that NPDia regulates macrophage polarization.
[0110] 4. Characterization of DMN / PLGA@Dia and evaluation of nanoparticle release after microneedle insertion
[0111] The spherical particle size of NPDia is 181.8±48.51nm ( Figure 6 A and B). After NPDia was completely mixed with low molecular weight hyaluronic acid (200 mg / mL), the mixture appeared gelatinous ( Figure 6 C), then follow Figure 6 DMN / PLGA@Dia was prepared using the process shown in FIG. Figure 6 E shows the overall appearance of the microneedle. Each microneedle has 2×5×12 needle tips, divided into two arrays. After removing the edges, it can be evenly applied to the two ankle joints of the rat, and its size is appropriate. From the ultra-deep microscopy image ( Figure 6 H) and SEM images ( Figure 6 F) shows that the needle tip is conical. DMN / PLGA RDBIt was shown that nanoparticles can be evenly distributed in the microneedles ( Figure 6 G). H&E staining showed that the DMN / PLGA@Dia patch could form channels in the skin ( Figure 6 The results of the texture analyzer showed that the hardness of DMN / PLGA@Dia was partially improved compared with the blank microneedles ( Figure 6 This is because the addition of nanoparticles can increase the strength of the microneedles, and the adhesion and elasticity are significantly increased ( Figure 6 K and N), the resilience and cohesion are partially reduced ( Figure 6 of L and M).
[0112] To verify that the nanoparticles can be released from the microneedles, a rat model of Achilles tendon-bone insertion injury was used. After reducing ankle swelling, DMN@PLGA Dir .DMN@PLGA Dir Typical fluorescence images of Figure 7 As shown in A. In vivo imaging of the rat ankle skin was performed after 1d, 2d, 3d, 4d, 5d, 6d and 7d of placement ( Figure 7 B and C). To prevent the microneedles from falling off due to the mice's activities, a film patch and medical tape were used to reinforce them. However, most mice shed the microneedles within 48 hours. Figure 7 It can be seen from the C that after removing the microneedle, the fluorescent signal at the ankle joint can still be detected. This indicates that the nanoparticles in the microneedle have been successfully released. The quantitative analysis results showed that the fluorescent signal at the ankle joint of the rat lasted for 7 days and showed a downward trend ( Figure 7 D). At 3d and 7d, the rat organs were removed for in vitro imaging. After removing the surface skin, fluorescence was still detected in the ankle joint ( Figure 7 E). After 7 days, DMN@PLGA Dir There was no significant difference in fluorescence intensity between the group and the control group ( Figure 7 This indicates that the nanoparticles can continuously deliver drugs to the subcutaneous area. In addition, quantitative fluorescence analysis of the rat heart, liver, spleen, lung, and kidney showed that the metabolic organs of the nanoparticles were mainly the liver and kidney ( Figure 7 F, HL).
[0113] 5. DMN / PLGA@Dia can reduce oxidative damage in the Achilles tendon insertion point rupture model and promote the healing of tendon-bone insertion tissue
[0114] To verify the in vivo effect of DMN / PLGA@Dia in promoting tendon-bone healing, a rat Achilles tendon-bone insertion injury model was established. The role of DMN / PLGA@Dia in combating oxidative stress was first studied. At 4 and 8 weeks, the ROS / RNS levels in the DMN / PLGA@Dia group continued to decrease compared with the control and NC groups (P<0.01), with the high-dose group being the most significant ( Figure 8 MDA, a marker of lipid peroxidation damage in mitochondria, was also significantly improved in the DMN / PLGA@Dia group ( Figure 8 B and E). Antioxidant enzymes are the main line of defense for scavenging ROS, protecting mitochondrial content, and stabilizing mitochondrial membranes. SOD is the first line of defense against oxidative stress. In this result, the SOD level of the DMN / PLGA@Dia group was significantly restored ( Figure 8 C and F). Figure 8 G shows the gross pictures of the Achilles tendon-bone of the five groups at the 4th and 8th weeks. From the overall picture, it can be seen that the Achilles tendon-bone tissue of the DMN / PLGA@Dia treatment group was obviously milky white and less adhesive, similar to the normal Achilles tendon-bone tissue. The Achilles tendon-bone tissue of the control group and the NC group was transparent and had severe adhesion. In the biomechanical test, all tissues ruptured at the injury site. At week 4, the maximum load of the medium-dose DMN / PLGA@Dia group and the high-dose DMN / PLGA@Dia group was significantly higher than that of the control group and the NC group ( Figure 8 At week 8, only the maximum load of the high-dose DMN / PLGA@Dia group was significantly higher than that of the control group and the NC group ( Figure 8 This may be because the adhesion of the control and NC groups was heavier, and these scar tissues could also increase the maximum load to a certain extent. In order to measure the effect of DMN / PLGA@Dia on Achilles tendon bone tissue, at week 4 ( Figure 8 J) and Week 8 ( Figure 8 The protein levels of SCX, Col I, and Col III were detected in the DMN / PLGA@Dia group (K). SCX is expressed during tendon development and plays an important role in guiding tendon wound healing. In addition, during the healing process of tendon-bone insertion, the newly formed collagen fibers at the insertion site are type III and gradually transform into type I. In this result, at weeks 4 and 8, the expression of SCX and Col I in the DMN / PLGA@Dia-treated group was significantly increased compared with the control group and the NC group ( Figure 8 At weeks 4 and 8, the expression of Col III in the DMN / PLGA@Dia-treated group was significantly decreased compared with the control and NC groups ( Figure 8 of N and Q).
[0115] HE and Masson staining results showed that the connective tissue in the DMN / PLGA@Dia group was organized and interlaced at week 4. However, the collagen tissue in the control and NC groups was sparsely distributed and adhered irregularly to the insert. At week 8, the direction of the collagen fibers in each group at the implant site was more regular than that in the early stage ( Fig. 9 A, Sirius red staining, thick orange or bright red fibers are Col I, thin green fibers are Col III or fibrochondrocytes). In particular, the insertion sites of the low-dose and medium-dose DMN / PLGA@Dia groups were more organized than those of the other groups. In semiquantitative analysis, the MHSS scores of the control and NC groups at weeks 4 and 8 were significantly lower than those of the DMN / PLGA@Dia group ( Fig. 9 Safranin O staining results at 4 weeks showed that the chondrocytes in the DMN / PLGA@Dia group were more mature and the transition between them and fibroblasts was more orderly, which was more obvious at 8 weeks ( Fig. 9 A). Sirius red staining of tissue sections 4 weeks after surgery showed that the DMN / PLGA@Dia group was more regular and orderly than the control group and the NC group ( Fig. 9 A). Semi-quantitative analysis based on Sirius red staining brightness at 4 weeks showed that the type I collagen content in the control group was significantly lower than that in the DMN / PLGA@Dia group ( Fig. 9 At week 8, the content of type I collagen in the DMN / PLGA@Dia group was significantly higher than that in the control group and the NC group ( Fig. 9 At week 4, immunohistochemistry results showed that the expression of type I collagen in the control group and NC group was significantly lower than that in the DMN / PLGA@Dia group ( Fig. 9 H and I). The expression of type III collagen in the control group and NC group was significantly higher than that in the medium-dose DMN / PLGA@Dia group and the high-dose DMN / PLGA@Dia group ( Fig. 9 H and J). At 8 weeks, immunohistochemistry results showed that the expression of type I collagen in the control group and NC group was significantly lower than that in the low-dose DMN / PLGA@Dia group and the medium-dose DMN / PLGA@Dia group ( Fig. 9 The expression of type III collagen in the control group was significantly higher than that in the low-dose DMN / PLGA@Dia group and the medium-dose DMN / PLGA@Dia group ( Fig. 9 K and M). The results of immunohistochemistry were consistent with those of immunoblotting. Considering the importance of type I and type III collagen in tendon-bone healing, it is speculated that diacerein may promote healing in two ways. First, diacerein may increase the amount of type III collagen and early neovascularization, and second, diacerein may accelerate the conversion of type III collagen to type I collagen. Both of these will promote tendon-bone healing, and the second possibility is more likely. However, further experiments are needed to verify this.
[0116] 6. In vivo DMN / PLGA@Dia improves functional recovery after Achilles tendon-bone injury
[0117] In order to obtain further accurate and objective evaluation of DMN / PLGA@Dia performance, including gait stability, the CatWalk test was performed on rats in different groups. The results showed that at 4 and 8 weeks, the DMN / PLGA@Dia-treated group showed a trend of normal hindlimb footprints compared with the control group ( Fig.10 A and B). Standing time, speed, and step length are commonly used indicators for evaluating gait. At 4 and 8 weeks, the DMN / PLGA@Dia treatment group ( Fig.10 Compared with control rats, rats treated with DMN / PLGA@Dia showed reduced ground contact time, increased swing speed and step circumference during gait walking. In addition, previous studies have shown that healthy rats do not put their heels on the ground during a series of walking movements, while rats with Achilles tendon injuries do. Typical footprint images showed that at 4 and 8 weeks, control rats put their heels on the ground, while DMN / PLGA@Dia-treated rats were able to perform heel-raising exercises. This is consistent with previous research results. At the same time, paw stress maps at 4 and 8 weeks also showed that rats in the treatment group were able to withstand greater strain ( Fig.11 ). This suggests that DMN / PLGA@Dia promotes functional recovery after Achilles tendon insertion injury.
[0118] 7. Diacerein regulates macrophage M1 / M2 polarization
[0119] The regulatory effect of DMN / PLGA@Dia on the immune microenvironment during tendon-bone insertion healing was further explored. Pathologically, oxidative stress mediates inflammatory activation, including the activation of M1 macrophages and the unrestricted secretion of proinflammatory factors. Therefore, the polarization direction of macrophages and the secretion of inflammatory factors during tendon-bone healing can be studied by DMN / PLGA@Dia intervention. For macrophage polarization, M1 macrophages were labeled with CD86 and M2 macrophages were labeled with CD206 for tissue immunofluorescence staining. Quantitative comparison between 4 and 8 weeks showed that DMN / PLGA@Dia intervention resulted in a significantly lower proportion of CD86-positive cells than the control and NC groups, while showing a higher proportion of CD206-positive cells than the control and NC groups ( Fig.12 AH). This indicates that macrophages are polarized toward M2. Subsequently, the secretion of inflammatory factors and anti-inflammatory factors in tendon and bone tissue was detected at 4 and 8 weeks. ELISA results showed that the secretion of inflammatory factor IL-1β was significantly reduced in the DMN group at 4 and 8 weeks. TNF-α showed a downward trend. The secretion of IL-6 and IL-10 increased significantly ( Fig.12These results suggest that the immunomodulatory effect of DMN / PLGA@Dia triggers a shift in the healing immune microenvironment of the tendon-bone insert from pro-inflammatory to anti-inflammatory.
[0120] In addition, organ HE staining, blood biochemical tests and hemolysis tests were performed to confirm the biocompatibility of DMN / PLGA@Dia. The results showed that there were no obvious pathological changes in the main organs ( Fig.13 AB), there was no difference in blood biochemical indexes between the DMN / PLGA@Dia group and the control group ( Fig.13 The results of the hemolysis test on the nanoparticle NPDia showed that the hemolysis rate of NPDia was less than 5% ( Fig.14 ).
[0121] Conclusion
[0122] The above experimental results show that DMN / PLGA@Dia can be used as an effective and universal treatment method to promote tendon-bone repair and significantly improve the immune microenvironment. DMN / PLGA@Dia can accelerate tendon-bone healing by protecting tendon-bone cells from ROS attacks. At the same time, the above experiments also confirmed that DMN / PLGA@Dia can effectively reverse adverse immune responses by mediating the polarization of macrophages from M1 to M2. In addition, by using the rat Achilles tendon bone injury model, it was verified that DMN / PLGA@Dia can enhance functional recovery. Therefore, the present invention will provide an effective strategy for tendon-bone repair.
[0123] The embodiments described above are only descriptions of the preferred embodiments of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. Use of a soluble microneedle loaded with diacerein in the preparation of a drug or device for promoting tendon-bone healing, characterized in that: The diacerein-loaded soluble microneedles are prepared using polylactic acid-coglycolic acid nanoparticles as carriers, hyaluronic acid as a gelling agent, and diacerein as an active ingredient.
2. A method for preparing a soluble microneedle loaded with diacerein, characterized in that: The steps include: (1) preparing polylactic acid-coglycolic acid nanoparticles; (2) mixing the polylactic acid-coglycolic acid nanoparticles with diacerein to obtain diacerein nanoparticles; (3) mixing the diacerein nanoparticles with hyaluronic acid and shaping them in a microneedle mold to obtain the diacerein-loaded soluble microneedles.
3. The preparation method according to claim 2, characterized in that: In step (1), the preparation method of the polylactic acid-coglycolic acid nanoparticles is: mixing a dimethyl sulfoxide solution with a polylactic acid-coglycolic acid solution, adding an emulsifier for primary emulsification, adding an emulsifier again for secondary emulsification, and centrifuging to obtain the polylactic acid-coglycolic acid nanoparticles.
4. The preparation method according to claim 3, characterized in that: The concentration of the dimethyl sulfoxide solution is 50 μg / μL, and the concentration of the polylactic acid-coglycolic acid solution is 100 mg / mL; the volume ratio of the dimethyl sulfoxide solution to the polylactic acid-coglycolic acid solution is 0.2:
1.
5. The preparation method according to claim 3, characterized in that: The molar ratio of lactic acid to glycolic acid in the polylactic acid-coglycolic acid is 65:35, and the molecular weight of the polylactic acid-coglycolic acid is 40,000-75,000.
6. The preparation method according to claim 3, characterized in that: The emulsifier is polyvinyl alcohol.
7. The preparation method according to claim 3, characterized in that: The concentration of polyvinyl alcohol used in the first emulsification is 7%, and the amount used is 3 times the volume of the polylactic acid-coglycolic acid solution; the concentration of polyvinyl alcohol used in the second emulsification is 1%, and the amount used is 50 times the volume of the polylactic acid-coglycolic acid solution.
8. The preparation method according to claim 2, characterized in that: In step (2), the mass ratio of the polylactic acid-coglycolic acid nanoparticles to the diacerein is 10:(3-5).
9. The preparation method according to claim 2, characterized in that: In step (3), the concentration of the diacerein nanoparticles in the diacerein-loaded soluble microneedles is 1.25-5 mg / ml, and the concentration of the hyaluronic acid in the diacerein-loaded soluble microneedles is 200 mg / ml.
10. A soluble microneedle loaded with diacerein prepared by the preparation method according to any one of claims 2 to 9.
